Collaborative, Licensing and Other Arrangements - Novo Nordisk - Additional Information (Details) - USD ($) $ in Millions |
12 Months Ended | |
|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2015 |
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Performance deliverable period for license and transfer of technology and knowhow | 60 days | |
| Upfront payment recognized as revenue | $ 5.0 | |
| Collaborative Arrangement [Member] | Novo Nordisk [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Upfront payment received | $ 5.0 | |
| Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 290.0 | |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Eligible milestone payments receivable upon achievement of development regulatory and commercial milestones. No definition available.
|
| X | ||||||||||
- Definition Performance deliverable period for license and transfer of technology and knowhow No definition available.
|
| X | ||||||||||
- Definition Proceeds from upfront payment. No definition available.
|
| X | ||||||||||
- Definition Upfront fee recognized as revenue. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|